430 related articles for article (PubMed ID: 8378359)
1. Prevention of experimental autoimmune myasthenia gravis by manipulation of the immune network with a complementary peptide for the acetylcholine receptor.
Araga S; LeBoeuf RD; Blalock JE
Proc Natl Acad Sci U S A; 1993 Sep; 90(18):8747-51. PubMed ID: 8378359
[TBL] [Abstract][Full Text] [Related]
2. Use of complementary peptides and their antibodies in B-cell-mediated autoimmune disease: prevention of experimental autoimmune myasthenia gravis with a peptide vaccine.
Araga S; Blalock JE
Immunomethods; 1994 Oct; 5(2):130-5. PubMed ID: 7874437
[TBL] [Abstract][Full Text] [Related]
3. Prevention of experimental autoimmune myasthenia gravis by a monoclonal antibody to a complementary peptide for the main immunogenic region of the acetylcholine receptors.
Araga S; Galin FS; Kishimoto M; Adachi A; Blalock JB
J Immunol; 1996 Jul; 157(1):386-92. PubMed ID: 8683141
[TBL] [Abstract][Full Text] [Related]
4. On the initial trigger of myasthenia gravis and suppression of the disease by antibodies against the MHC peptide region involved in the presentation of a pathogenic T-cell epitope.
Atassi MZ; Oshima M; Deitiker P
Crit Rev Immunol; 2001; 21(1-3):1-27. PubMed ID: 11642597
[TBL] [Abstract][Full Text] [Related]
5. Structural characterization of the main immunogenic region of the Torpedo acetylcholine receptor.
Morell SW; Trinh VB; Gudipati E; Friend A; Page NA; Agius MA; Richman DP; Fairclough RH
Mol Immunol; 2014 Mar; 58(1):116-31. PubMed ID: 24333757
[TBL] [Abstract][Full Text] [Related]
6. Specificity of the T cell immune response to acetylcholine receptor in experimental autoimmune myasthenia gravis. Response to subunits and synthetic peptides.
Fujii Y; Lindstrom J
J Immunol; 1988 Mar; 140(6):1830-7. PubMed ID: 2450133
[TBL] [Abstract][Full Text] [Related]
7. Suppression of experimental autoimmune myasthenia gravis by nasal administration of acetylcholine receptor.
Ma CG; Zhang GX; Xiao BG; Link J; Olsson T; Link H
J Neuroimmunol; 1995 Apr; 58(1):51-60. PubMed ID: 7537280
[TBL] [Abstract][Full Text] [Related]
8. Suppression of experimental autoimmune myasthenia gravis by oral administration of acetylcholine receptor.
Wang ZY; Qiao J; Link H
J Neuroimmunol; 1993 May; 44(2):209-14. PubMed ID: 8505410
[TBL] [Abstract][Full Text] [Related]
9. B cell responses to acetylcholine receptor in rats orally tolerized against experimental autoimmune myasthenia gravis.
Wang ZY; Huang J; Olsson T; He B; Link H
J Neurol Sci; 1995 Feb; 128(2):167-74. PubMed ID: 7537794
[TBL] [Abstract][Full Text] [Related]
10. Depletion of CD8+ T cells suppresses the development of experimental autoimmune myasthenia gravis in Lewis rats.
Zhang GX; Ma CG; Xiao BG; Bakhiet M; Link H; Olsson T
Eur J Immunol; 1995 May; 25(5):1191-8. PubMed ID: 7774622
[TBL] [Abstract][Full Text] [Related]
11. Synthetic peptides fail to induce nasal tolerance to experimental autoimmune myasthenia gravis.
Zhang GX; Shi FD; Zhu J; Xiao BG; Levi M; Wahren B; Yu LY; Link H
J Neuroimmunol; 1998 May; 85(1):96-101. PubMed ID: 9627002
[TBL] [Abstract][Full Text] [Related]
12. Sequence analysis of anti-AChR antibodies in experimental autoimmune myasthenia gravis.
Graus Y; Meng F; Vincent A; van Breda Vriesman P; de Baets M
J Immunol; 1995 Jun; 154(12):6382-96. PubMed ID: 7539019
[TBL] [Abstract][Full Text] [Related]
13. Suppression of experimental autoimmune myasthenia gravis by epitope-specific neonatal tolerance to synthetic region alpha 146-162 of acetylcholine receptor.
Shenoy M; Oshima M; Atassi MZ; Christadoss P
Clin Immunol Immunopathol; 1993 Mar; 66(3):230-8. PubMed ID: 7679342
[TBL] [Abstract][Full Text] [Related]
14. B cell autoimmunity to acetylcholine receptor and its subunits in Lewis rats over the course of experimental autoimmune myasthenia gravis.
Wang ZY; Link H; Qiao J; Olsson T; Huang WX
J Neuroimmunol; 1993 Jun; 45(1-2):103-12. PubMed ID: 8331155
[TBL] [Abstract][Full Text] [Related]
15. Spectrotypic analysis of antibodies to acetylcholine receptors in experimental autoimmune myasthenia gravis.
Bionda A; De Baets MH; Tzartos SJ; Lindstrom JM; Weigle WO; Theophilopoulos AN
Clin Exp Immunol; 1984 Jul; 57(1):41-50. PubMed ID: 6611231
[TBL] [Abstract][Full Text] [Related]
16. Modulation of the anti-acetylcholine receptor response and experimental autoimmune myasthenia gravis by recombinant fragments of the acetylcholine receptor.
Barchan D; Asher O; Tzartos SJ; Fuchs S; Souroujon MC
Eur J Immunol; 1998 Feb; 28(2):616-24. PubMed ID: 9521072
[TBL] [Abstract][Full Text] [Related]
17. Modulation of anti-acetylcholine receptor antibody specificities and of experimental autoimmune myasthenia gravis by synthetic peptides.
Souroujon MC; Carmon S; Fuchs S
Immunol Lett; 1992 Sep; 34(1):19-25. PubMed ID: 1282497
[TBL] [Abstract][Full Text] [Related]
18. [Antibodies in myasthenia gravis].
Eymard B
Rev Neurol (Paris); 2009 Feb; 165(2):137-43. PubMed ID: 19162288
[TBL] [Abstract][Full Text] [Related]
19. Suppression of development of experimental autoimmune myasthenia gravis with isogeneic monoclonal anti-idiotopic antibody.
Agius MA; Richman DP
J Immunol; 1986 Oct; 137(7):2195-8. PubMed ID: 3489757
[TBL] [Abstract][Full Text] [Related]
20. Nasal tolerance in experimental autoimmune myasthenia gravis (EAMG): induction of protective tolerance in primed animals.
Shi FD; Bai XF; Li HL; Huang YM; Van der Meide PH; Link H
Clin Exp Immunol; 1998 Mar; 111(3):506-12. PubMed ID: 9528890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
